Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(04): 240-257
DOI: 10.4103/sajc.sajc_139_19
Letter to the Editor

Metachronous muscle metastasis in a case of metastatic gallbladder cancer with TP35 gene mutation: A rare case report

Joydeep Ghosh
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal
,
Sandip Ganguly
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal
,
Deepak Dabkara
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal
,
Bivas Biswas
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal
,
Arghya Chatterjee
Department of Radiology, Tata Medical Center, Kolkata, West Bengal
,
Sumit Mukhopadhyay
Department of Radiology, Tata Medical Center, Kolkata, West Bengal
,
Aditi Chandra
Department of Radiology, Tata Medical Center, Kolkata, West Bengal
,
Saugata Sen
Department of Radiology, Tata Medical Center, Kolkata, West Bengal
,
Debdeep Dey
Department of Pathology, Tata Medical Center, Kolkata, West Bengal
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
14 December 2020

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist 2010;15:168-81.
  • 2 Kokudo N, Makuuchi M, Natori T, Sakamoto Y, Yamamoto J, Seki M, et al. Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg 2003;138:741-50.
  • 3 Ohtani T, Shirai Y, Tsukada K, Muto T, Hatakeyama K. Spread of gallbladder carcinoma: CT evaluation with pathologic correlation. Abdom Imaging 1996;21:195-201.
  • 4 Singh S, Bhojwani R, Singh S, Bhatnagar A, Saran RK, Agarwal AK, et al. Skeletal metastasis in gall bladder cancer. HPB (Oxford) 2007;9:71-2.
  • 5 Gilardi L, Paganelli G. Muscle metastases from gallbladder cancer. Ecancermedicalscience 2011;5:236.
  • 6 Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
  • 7 Sharma A, Shukla NK, Chaudhary SP, Sahoo R, Mohanti B, Deo SV, et al. Final results of a phase III randomized controlled trial comparing modified gemcitabine+oxaliplatin (mGEMOX) to gemcitabine+cisplatin in management of unresectable gall bladder cancer (GBC). J Clin Oncol 2016;34 Suppl 15:4077.
  • 8 Ramaswamy A, Ostwal V, Pinninti R, Kannan S, Bhargava P, Nashikkar C, et al. Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: A match pair analysis. J Hepatobiliary Pancreat Sci 2017;24:262-7.